Specifically, following treatment, OI type III samples had a significantly greater upregulation in TWIST1 (TRL and TRH), SOST (TRL and TRH), and DKK1 (TRL) above non‐OI untreated control levels. The gene discussed is SOST; the disease is osteogenesis imperfecta type 3.